Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience

Mackenzie Wilson (), Kednapa Thavorn (), Terry Hawrysh (), Ian D. Graham (), Harold Atkins (), Natasha Kekre (), Doug Coyle (), Manoj M. Lalu (), Dean A. Fergusson (), Kelvin K. W. Chan (), Daniel A. Ollendorf () and Justin Presseau ()
Additional contact information
Mackenzie Wilson: Ottawa Hospital Research Institute
Kednapa Thavorn: Ottawa Hospital Research Institute
Terry Hawrysh: Patient Partner
Ian D. Graham: Ottawa Hospital Research Institute
Harold Atkins: Ottawa Hospital Research Institute
Natasha Kekre: Ottawa Hospital Research Institute
Doug Coyle: University of Ottawa
Manoj M. Lalu: Ottawa Hospital Research Institute
Dean A. Fergusson: Ottawa Hospital Research Institute
Kelvin K. W. Chan: University of Toronto
Daniel A. Ollendorf: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
Justin Presseau: Ottawa Hospital Research Institute

PharmacoEconomics, 2022, vol. 40, issue 11, No 8, 1119-1130

Abstract: Abstract Background Traditionally, economic evaluations have engaged clinicians and policymakers; however, patients and their caregivers have insight that can ensure that the economic evaluation process appropriately reflects disease consequences and adequately addresses their priorities related to treatment. Objective We aimed to identify patient priorities to inform an early economic evaluation of chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Methods We conducted two online group discussions of four participants each, involving patients with experience of hematological cancer and a caregiver. We used an adapted version of the nominal group technique, a consensus-building discussion approach, to generate focused qualitative data. Results Patients and a caregiver acknowledged both the costs directly related to clinical care, such as the out-of-pocket cost of drugs, and the indirect treatment costs, such as the cost of transport, accommodation, and food. The emotional and physical toll of treatment and the influence of treatment on employment and education were additional costs emphasized by participants. Treatment benefits prioritized by participants included the efficacy of treatment, manageable side effects, improved quality of life, accessibility of treatment, and short treatment duration. Conclusions Engaging patients and caregivers in an early economic evaluation could help identify additional costs and benefits of therapies that are not typically recognized in economic evaluations but have the potential to increase the commercial viability of novel therapies. This research also demonstrates how patients and caregivers can be engaged at different levels in the development of early economic evaluation models.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-022-01180-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:40:y:2022:i:11:d:10.1007_s40273-022-01180-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-022-01180-4

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().